Hualong Mo , JieYing Liu , Zhengxi Su , Deng-Gao Zhao , Yan-Yan Ma , Kun Zhang , Qi Wang , Chun Fu , Yao Wang , Meiwan Chen , Burong Hu
{"title":"“异丙酸内酯/羟肟酸混合物作为有效的双重STAT3/HDAC抑制剂和自组装纳米颗粒用于癌症治疗”的勘误表[欧洲]。医学化学。(2024) 116765)","authors":"Hualong Mo , JieYing Liu , Zhengxi Su , Deng-Gao Zhao , Yan-Yan Ma , Kun Zhang , Qi Wang , Chun Fu , Yao Wang , Meiwan Chen , Burong Hu","doi":"10.1016/j.ejmech.2025.117307","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"286 ","pages":"Article 117307"},"PeriodicalIF":5.9000,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy” [Euro. J. Med. Chem. (2024) 116765]\",\"authors\":\"Hualong Mo , JieYing Liu , Zhengxi Su , Deng-Gao Zhao , Yan-Yan Ma , Kun Zhang , Qi Wang , Chun Fu , Yao Wang , Meiwan Chen , Burong Hu\",\"doi\":\"10.1016/j.ejmech.2025.117307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":314,\"journal\":{\"name\":\"European Journal of Medicinal Chemistry\",\"volume\":\"286 \",\"pages\":\"Article 117307\"},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2025-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0223523425000728\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425000728","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
Corrigendum to “Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy” [Euro. J. Med. Chem. (2024) 116765]
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.